首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Journal of pharmaceutical health care and sciences

缩写:

ISSN:2055-0294

e-ISSN:2055-0294

IF/分区:1.2/Q4

文章目录 更多期刊信息

共收录本刊相关文章索引577
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yusuke Yagi,Yu Arakawa,Yukihiro Hamada et al. Yusuke Yagi et al.
Background: The global crisis of antimicrobial resistance (AMR) necessitates robust antimicrobial stewardship. The World Health Organization's (WHO) Access, Watch, Reserve (AWaRe) classification is a key tool for guiding ...
Daisuke Kikuchi,Taku Obara,Shiro Hatakeyama et al. Daisuke Kikuchi et al.
Background: Japanese traditional (Kampo) medicines are commonly prescribed in clinical practice, with increasing evidence supporting their use during pregnancy. The efficacy and safety of Kampo medicines during pregnancy ...
Yuki Sato,Yudai Takatani,Shunsaku Nakagawa et al. Yuki Sato et al.
Background: Antibiotics are crucial for treating infectious diseases, but their appropriate use is essential to minimize adverse reactions and resistance. This study evaluated the effectiveness of protocol-based pharmacot...
Hirofumi Koike,Maho Taguchi,Akihiro Koide et al. Hirofumi Koike et al.
Background: The implementation of local formularies in Japan began in November 2018 in the Sakata area of Yamagata Prefecture. A local formulary is a regional list of recommended pharmaceuticals selected based on comprehe...
Kazumasa Kotake,Toshiki Nakamura,Yuki Nakano et al. Kazumasa Kotake et al.
Background: In December 2019, a nationwide registration system with strict distribution controls for extended-release methylphenidate (ER-MPH) was introduced to prevent inappropriate use while maintaining treatment access...
Ryota Kanno,Yoshitaka Saito,Yoh Takekuma et al. Ryota Kanno et al.
Background: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line trea...